NKT Therapeutics, Inc. (the “Company”) is a biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (“NKT”) cells. NKT cells are a rare but central component of the immune system that plays a pivotal role in human health and disease. Upon exposure to glycolipid antigens, NKT cells secrete high levels of specific cytokines that stimulate the innate and adaptive arms of the immune system to eliminate these pathogens. During periods of repeated exposure to immune challenge, NKT cells play a regulatory role controlling the type and magnitude of the adaptive arm of the immune system to regulate antibody and cell mediated immunity. Recent evidence has clearly established the importance of NKT cells in human health and disease. The mission of NKT Therapeutics is to use the Company’s expertise to develop a pipeline of first-in-class NKT based therapeutics to treat sickle cell anemia, autoimmune diseases and inflammatory diseases, cancer, asthma and dermatitis.


We are targeting a unique subset of T cells called NKT cells which offers the opportunity to develop selective immune modulators with the potential to treat cancer, infectious disease, autoimmune diseases (e.g, SLE, T1D, MS, IBD), asthma and dermatitis. Our lead programs are based upon a unique set of antibodies that targets the invariant T cell receptor present of NKT cells.  We are developing antibody therapeutics that can either inactivate (NKTT120) or activate (NKTT320) NKT cell function.